TNFSF10 and plasma cell myeloma: In this paper we reported in vitro viability tests performed in two different cell lines (A2058, melanoma; U266, multiple myeloma) to define the potential synergistic activity between the proteasome inhibitor BOZ and the TRAIL-inducer TIC10.